merged_adhd-life-expectancy.txt
<other>The article provides specific details about the British study and other related studies, but does not directly compare methodologies or discuss potential confounding variables in detail.</other>

<question_number>1</question_number>
<answer>The British study used all-cause mortality data to estimate life expectancy, while the 2022 JAMA Pediatrics meta-analysis focused on deaths from unnatural causes.</answer>

<question_number>2</question_number>
<answer>Without knowing the specific causes of death, preventive strategies might overlook critical factors like suicidality, diet, exercise, or depression.</answer>

<question_number>3</question_number>
<answer>The British study highlights early mortality, while the diabetes analogy suggests lifelong management, implying that adherence to management strategies might not have been consistent over time.</answer>

<question_number>4</question_number>
<answer>The underdiagnosis caveat suggests many cases were missed, yet rising adult diagnosis rates indicate more people are being identified, which could mean the mortality risks are not as high as the study suggests.</answer>

<question_number>5</question_number>
<answer>The article does not mention the Adderall shortage during the British study's observation window, so it does not create a confounding variable for the study's mortality calculations.</answer>